Pesquisa | BVS Violência e Saúde

1.

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

McGregor, B A; Sonpavde, G P; Kwak, L; Regan, M M; Gao, X; Hvidsten, H; Mantia, C M; Wei, X X; Berchuck, J E; Berg, S A; Ravi, P K; Michaelson, M D; Choueiri, T K; Bellmunt, J.

Ann Oncol ; 35(1): 91-97, 2024 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-37871703

2.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

Balar, A V; Castellano, D E; Grivas, P; Vaughn, D J; Powles, T; Vuky, J; Fradet, Y; Lee, J-L; Fong, L; Vogelzang, N J; Climent, M A; Necchi, A; Petrylak, D P; Plimack, E R; Xu, J Z; Imai, K; Moreno, B H; Bellmunt, J; de Wit, R; O'Donnell, P H.

Ann Oncol ; 34(3): 289-299, 2023 03.

Artigo em Inglês | MEDLINE | ID: mdl-36494006

3.

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.

Powles, T; Bellmunt, J; Comperat, E; De Santis, M; Huddart, R; Loriot, Y; Necchi, A; Valderrama, B P; Ravaud, A; Shariat, S F; Szabados, B; van der Heijden, M S; Gillessen, S.

Ann Oncol ; 35(6): 485-490, 2024 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-38490358

4.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet, Y; Bellmunt, J; Vaughn, D J; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D P; Choueiri, T K; Necchi, A; Gerritsen, W; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Nam, K; Frenkl, T L; Perini, R F; de Wit, R; Bajorin, D F.

Ann Oncol ; 30(6): 970-976, 2019 06 01.

Artigo em Inglês | MEDLINE | ID: mdl-31050707

5.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees.

Horwich, A; Babjuk, M; Bellmunt, J; Bruins, H M; De Reijke, T M; De Santis, M; Gillessen, S; James, N; Maclennan, S; Palou, J; Powles, T; Ribal, M J; Shariat, S F; Van Der Kwast, T; Xylinas, E; Agarwal, N; Arends, T; Bamias, A; Birtle, A; Black, P C; Bochner, B H; Bolla, M; Boormans, J L; Bossi, A; Briganti, A; Brummelhuis, I; Burger, M; Castellano, D; Cathomas, R; Chiti, A; Choudhury, A; Compérat, E; Crabb, S; Culine, S; De Bari, B; DeBlok, W; De Visschere, P J L; Decaestecker, K; Dimitropoulos, K; Dominguez-Escrig, J L; Fanti, S; Fonteyne, V; Frydenberg, M; Futterer, J J; Gakis, G; Geavlete, B; Gontero, P; Grubmüller, B; Hafeez, S; Hansel, D E.

Ann Oncol ; 30(11): 1697-1727, 2019 11 01.

Artigo em Inglês | MEDLINE | ID: mdl-31740927

6.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias, A; Tzannis, K; Harshman, L C; Crabb, S J; Wong, Y-N; Kumar Pal, S; De Giorgi, U; Ladoire, S; Agarwal, N; Yu, E Y; Niegisch, G; Necchi, A; Sternberg, C N; Srinivas, S; Alva, A; Vaishampayan, U; Cerbone, L; Liontos, M; Rosenberg, J; Powles, T; Bellmunt, J; Galsky, M D.

Ann Oncol ; 29(2): 361-369, 2018 02 01.

Artigo em Inglês | MEDLINE | ID: mdl-29077785

7.

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Bellmunt, J; Eigl, B J; Senkus, E; Loriot, Y; Twardowski, P; Castellano, D; Blais, N; Sridhar, S S; Sternberg, C N; Retz, M; Pal, S; Blumenstein, B; Jacobs, C; Stewart, P S; Petrylak, D P.

Ann Oncol ; 28(10): 2481-2488, 2017 Oct 01.

Artigo em Inglês | MEDLINE | ID: mdl-28961845

8.

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Fizazi, K; Ulys, A; Sengeløv, L; Moe, M; Ladoire, S; Thiery-Vuillemin, A; Flechon, A; Guida, A; Bellmunt, J; Climent, M A; Chowdhury, S; Dumez, H; Matouskova, M; Penel, N; Liutkauskiene, S; Stachurski, L; Sternberg, C N; Baton, F; Germann, N; Daugaard, G.

Ann Oncol ; 28(11): 2741-2746, 2017 Nov 01.

Artigo em Inglês | MEDLINE | ID: mdl-29059273

9.

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Powles, T; Bellmunt, J; Comperat, E; De Santis, M; Huddart, R; Loriot, Y; Necchi, A; Valderrama, B P; Ravaud, A; Shariat, S F; Szabados, B; van der Heijden, M S; Gillessen, S.

Ann Oncol ; 33(3): 244-258, 2022 03.

Artigo em Inglês | MEDLINE | ID: mdl-34861372

10.

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

Bellmunt, J; Kerst, J M; Vázquez, F; Morales-Barrera, R; Grande, E; Medina, A; González Graguera, M B; Rubio, G; Anido, U; Fernández Calvo, O; González-Billalabeitia, E; Van den Eertwegh, A J M; Pujol, E; Perez-Gracia, J L; González Larriba, J L; Collado, R; Los, M; Maciá, S; De Wit, R.

Ann Oncol ; 28(7): 1517-1522, 2017 Jul 01.

Artigo em Inglês | MEDLINE | ID: mdl-28419193

11.

New advances in genitourinary cancer: evidence gathered in 2014.

Suárez, C; Puente, J; Gallardo, E; Méndez-Vidal, M J; Climent, M A; León, L; Olmos, D; García del Muro, X; González-Billalabeitia, E; Grande, E; Bellmunt, J; Mellado, B; Maroto, P; González del Alba, A.

Cancer Metastasis Rev ; 34(3): 443-64, 2015 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-26227584

12.

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

Raggi, D; Miceli, R; Sonpavde, G; Giannatempo, P; Mariani, L; Galsky, M D; Bellmunt, J; Necchi, A.

Ann Oncol ; 27(1): 49-61, 2016 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-26487582

13.

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

De Santis, M; Wiechno, P J; Bellmunt, J; Lucas, C; Su, W-C; Albiges, L; Lin, C-C; Senkus-Konefka, E; Flechon, A; Mourey, L; Necchi, A; Loidl, W C; Retz, M M; Vaissière, N; Culine, S.

Ann Oncol ; 27(3): 449-54, 2016 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-26673352

14.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Chi, K N; Kheoh, T; Ryan, C J; Molina, A; Bellmunt, J; Vogelzang, N J; Rathkopf, D E; Fizazi, K; Kantoff, P W; Li, J; Azad, A A; Eigl, B J; Heng, D Y C; Joshua, A M; de Bono, J S; Scher, H I.

Ann Oncol ; 27(3): 454-60, 2016 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-26685010

15.

Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.

Orsola, A; Werner, L; de Torres, I; Martin-Doyle, W; Raventos, C X; Lozano, F; Mullane, S A; Leow, J J; Barletta, J A; Bellmunt, J; Morote, J.

Br J Cancer ; 112(3): 468-74, 2015 Feb 03.

Artigo em Inglês | MEDLINE | ID: mdl-25535728

16.

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Bellmunt, J; Mullane, S A; Werner, L; Fay, A P; Callea, M; Leow, J J; Taplin, M E; Choueiri, T K; Hodi, F S; Freeman, G J; Signoretti, S.

Ann Oncol ; 26(4): 812-817, 2015 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-25600565

17.

New agents for prostate cancer.

Agarwal, N; Di Lorenzo, G; Sonpavde, G; Bellmunt, J.

Ann Oncol ; 25(9): 1700-1709, 2014 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-24658665

18.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias, A; Tzannis, K; Harshman, L C; Crabb, S J; Wong, Y-N; Kumar Pal, S; De Giorgi, U; Ladoire, S; Agarwal, N; Yu, E Y; Niegisch, G; Necchi, A; Sternberg, C N; Srinivas, S; Alva, A; Vaishampayan, U; Cerbone, L; Liontos, M; Rosenberg, J; Powles, T; Bellmunt, J; Galsky, M D.

Ann Oncol ; 30(11): 1841, 2019 11 01.

Artigo em Inglês | MEDLINE | ID: mdl-31868903

19.

PD-L1 expression in nonclear-cell renal cell carcinoma.

Choueiri, T K; Fay, A P; Gray, K P; Callea, M; Ho, T H; Albiges, L; Bellmunt, J; Song, J; Carvo, I; Lampron, M; Stanton, M L; Hodi, F S; McDermott, D F; Atkins, M B; Freeman, G J; Hirsch, M S; Signoretti, S.

Ann Oncol ; 25(11): 2178-2184, 2014 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-25193987

20.

Epidemiological evolution and economic impact of the COVID-19 pandemic in the European Union and worldwide and effects of control strategies on them: An ecological study.

Caylà, J A; Bellmunt, J M; Jansà, J M; Marco, A; Millet, J P.

Semergen ; 50(6): 102274, 2024 Jun 11.

Artigo em Inglês | MEDLINE | ID: mdl-38865758

BVS Violência e Saúde

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

New advances in genitourinary cancer: evidence gathered in 2014.

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

New agents for prostate cancer.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

PD-L1 expression in nonclear-cell renal cell carcinoma.

Epidemiological evolution and economic impact of the COVID-19 pandemic in the European Union and worldwide and effects of control strategies on them: An ecological study.